ICCC - ImmuCell Corporation Stock Analysis

Stock Taper

OPPORTUNITY RADAR SCREENER COMPARE ANY 2 STOCKS

ICCC

IMMUCELL CORPORATION

NASDAQ

$9.75

▲ UP 0.00% (0.00)

KEY STATISTICS

Market Cap$89.02 M

52w High$12.10

52w Low$4.52

Dividend Yield—

Frequency—

P/E-162.50

Volume11.26K

Shares Out.9.05M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

F. Olivier Te Boekhorst

COMPENSATION 2026

Salary$69,231

Stock Awards$503,269

Incentive Plan Pay$0

All Other Comp.$3,434

Total$675,934

ABOUT

SECTOR

Healthcare

WENT PUBLIC

May 5, 1987

METHOD OF GOING PUBLIC

SPAC

FULL TIME EMPLOYEES

UPCOMING EARNINGS

DateNov 12, 2026

DayThursday

Rev. Est.$5.40M

NOV

THU

SPLIT RECORD

DATE	TYPE	RATIO
1990-07-25	Reverse	1:100

ETFS HOLDING THIS STOCK

ETFS HOLDING

LISTED HERE

RANKED BY POSITION SIZE

INSTITUTIONAL OWNERSHIP

SHARES OWNED

12.93%

HOLDERS

TOP 8 OF 34 · RANKED BY POSITION SIZE

Renaissance Technologies LLC

157.3K sh

$983.06K

Cresset Asset Management, LLC

Dauntless Investment Group, LLC

87.1K sh

$544.51K

Meristem Family Wealth, LLC

85.5K sh

$825K

Geode Capital Management, LLC

72.3K sh

$444.47K

PRICE

$9.75 ▲ UP 0.00% (+$0.00)

OVERLAYS

About ImmuCell Corporation

https://immucell.com ↗

ImmuCell Corporation develops and markets animal health products, including preventive and treatment solutions for dairy and beef cattle, focusing on disease prevention, detection, and nutritional support.

INDUSTRY

Biotechnology

A PRODUCT IMMUCELL CORPORATION IS KNOWN FOR

First Defense Tri-Shield

First Defense Tri-Shield is an oral gel that quickly protects newborn calves from E. coli, coronavirus, and rotavirus, with ImmuCell now prioritizing its market expansion and manufacturing after shifting focus from Re-Tain.

COMPETITORS

COMPETITOR

ImmuCell in 2025

SENTIMENT: − NEGATIVE

REGULATORY · DECEMBER 2025

ImmuCell Halts Development of Key Drug Re-Tain® After FDA Setback, Pivots to Core Product Line

ImmuCell Corporation announced it received an 'Incomplete Letter' from the U.S. Food and Drug Administration (FDA) on December 23, 2025, for its New Animal Drug Application for Re-Tain®, a treatment for subclinical mastitis in dairy cows. This was due to unresolved issues at its contract manufacturer. Consequently, the company announced a strategic pivot to pause further investment in Re-Tain® and focus on expanding its existing and profitable First Defense® product line, including a 50% increase in its sales force.

PRODUCT DISCONTINUATION · DECEMBER 2025 · IN PROGRESS

ImmuCell Halts Re-Tain Development to Double Down on Core First Defense® Product Line

Following an 'Incomplete Letter' from the FDA regarding its new drug candidate Re-Tain®, ImmuCell's leadership made a decisive strategic pivot to suspend further investment in the product. The company is reallocating capital and resources to expand manufacturing and increase its sales force for its flagship First Defense® product line, signaling a focused effort to accelerate growth in its core market.